* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Lanvis (thioguanine) is a prescription chemotherapy medication used to treat certain types of leukemia, a cancer that affects the blood and bone marrow.
It contains thioguanine, an active ingredient belonging to a class of medications called antimetabolites, specifically purine analogues. These medications are also classified as antineoplastic or cytotoxic chemotherapy agents.
Leukemia develops when abnormal blood-forming cells multiply uncontrollably in the bone marrow. The bone marrow is the soft tissue inside bones responsible for producing red blood cells, white blood cells, and platelets.
As leukemia cells accumulate, they can interfere with the production of healthy blood cells. This may lead to anemia, frequent infections, unusual bruising, bleeding, and fatigue.
Lanvis works by interfering with the production and function of genetic material inside rapidly dividing cells. This helps slow or stop the growth of leukemia cells.
According to the Canadian product monograph, Lanvis is indicated for the treatment of acute leukemia. Its use in chronic myeloid leukemia is more limited and is not a routine modern treatment.
Lanvis may be used in the treatment of acute myeloid leukemia (AML), a type of cancer that begins in the bone marrow and affects cells that normally develop into certain types of mature blood cells.
AML develops when immature blood-forming cells, commonly called myeloblasts, begin multiplying abnormally.
These cells do not mature and function as healthy blood cells should.
Instead, they accumulate in the bone marrow and may enter the bloodstream, interfering with normal blood cell production.
As the number of abnormal cells increases, the body may struggle to produce enough healthy red blood cells, white blood cells, and platelets.
Common symptoms of AML include:
AML is a rapidly progressing disease that generally requires prompt specialist treatment.
Lanvis may be included in certain chemotherapy regimens designed to reduce the number of leukemia cells.
Remission induction is the first major phase of treatment for many people with AML.
The goal is to destroy as many leukemia cells as possible and help the bone marrow resume producing healthy blood cells.
A complete remission generally means that leukemia cells are reduced below specific detection thresholds using standard testing and that blood cell counts have recovered to defined levels.
Thioguanine may be used alongside other chemotherapy medications during induction treatment.
Using several medications with different mechanisms may improve the ability to target leukemia cells.
However, Lanvis is not a standard component of every current AML treatment regimen. The choice of chemotherapy depends on factors such as age, general health, leukemia subtype, and genetic findings.
After remission is achieved, additional treatment is often necessary to reduce the risk of leukemia returning.
This stage is called remission consolidation.
Even when leukemia cells are no longer visible through routine testing, small numbers of cancer cells may remain in the body.
Consolidation therapy aims to eliminate remaining leukemia cells and support longer-lasting remission.
Thioguanine is an established chemotherapy option in certain induction and consolidation regimens for acute myeloid leukemia.
However, Lanvis is not recommended for long-term maintenance treatment because prolonged continuous exposure can cause serious liver toxicity.
Chronic myeloid leukemia (CML) is a type of blood cancer that causes excessive production of certain white blood cells.
Unlike AML, CML often develops more slowly, particularly during its early stage, known as the chronic phase.
Most cases of CML involve an abnormal gene called BCR::ABL1, which produces a protein that promotes uncontrolled blood cell growth.
Some people with CML may not experience noticeable symptoms when the condition is first diagnosed.
Others may develop fatigue, unexplained weight loss, night sweats, abdominal fullness, or discomfort caused by an enlarged spleen.
Thioguanine has shown activity against CML cells and was historically considered among chemotherapy options for the chronic phase of the disease.
However, Lanvis is not a standard treatment for CML today.
Modern CML treatment generally relies on targeted medications called tyrosine kinase inhibitors (TKIs), which block the abnormal BCR::ABL1 protein driving the disease.
Examples include imatinib, dasatinib, nilotinib, bosutinib, and asciminib.
These medications target the underlying molecular cause of most CML cases more specifically than traditional chemotherapy.
In unusual circumstances, a leukemia specialist may consider alternative treatments based on a patient’s clinical situation.
However, Lanvis should not be described as a routinely indicated treatment for CML that has failed to respond to other medications. Its Canadian labeling identifies acute leukemia as the approved indication.
Lanvis works by interfering with the ability of leukemia cells to produce and use genetic material needed for growth and reproduction.
Its active ingredient, thioguanine, belongs to a group of chemotherapy medications called purine analogues.
Purines are important building blocks of DNA and RNA.
DNA contains genetic instructions that control how cells grow, divide, and function. RNA helps cells use those instructions to produce proteins and perform essential activities.
Cancer cells need to produce new DNA and RNA as they multiply.
Thioguanine interferes with these processes, making it harder for leukemia cells to reproduce.
Thioguanine Acts as a Purine Analogue
Thioguanine has a chemical structure similar to guanine, one of the natural purine bases found in DNA and RNA.
Because of this similarity, cancer cells may process thioguanine in ways that resemble normal purines.
Once thioguanine enters a cell, it is converted into active substances called thioguanine nucleotides.
These metabolites interfere with normal nucleic acid production and function.
As a result, leukemia cells may lose their ability to grow and divide normally.
Interferes With DNA and RNA Production
DNA replication is essential for cell division.
Before a cell can divide into two new cells, it must copy its genetic material.
Thioguanine metabolites can become incorporated into DNA and RNA, disrupting important cellular processes.
This interference can damage genetic material and activate processes that lead to cell death.
Because leukemia cells often divide rapidly, they may be particularly vulnerable to medications that interfere with DNA production.
However, thioguanine can also affect healthy cells that divide quickly.
These include blood-forming cells in the bone marrow and cells lining the digestive tract.
This explains why Lanvis can cause side effects such as reduced blood cell counts, nausea, and mouth irritation.
Helps Reduce the Number of Leukemia Cells
As thioguanine interferes with cancer cell growth, the number of leukemia cells may decrease.
When used as part of an appropriate chemotherapy regimen, this can help the bone marrow recover its ability to produce healthy blood cells.
Reducing leukemia cells is an important goal of induction and consolidation treatment.
However, the effectiveness of Lanvis depends on several factors, including the type of leukemia, disease severity, treatment combination, and individual response.
Lanvis is generally used under the supervision of a specialist experienced in cancer chemotherapy.
Lanvis begins affecting cellular processes after the medication is absorbed and converted into active metabolites.
However, measurable improvement in leukemia does not necessarily occur immediately.
The response to chemotherapy depends on the type of leukemia, treatment schedule, and other medications used alongside Lanvis.
Your healthcare team will monitor treatment effectiveness through regular blood tests and, when necessary, bone marrow examinations.
These tests help determine whether leukemia cells are decreasing and whether healthy blood cell production is recovering.
Your healthcare provider may also assess changes in symptoms such as fatigue, unusual bleeding, or frequent infections.
It is important to understand that symptom improvement alone does not confirm remission.
A leukemia diagnosis and treatment response require specific laboratory and clinical assessments.
Lanvis is a powerful chemotherapy medication that requires careful monitoring throughout treatment.
One of its most important risks is myelosuppression, which occurs when the bone marrow produces fewer healthy blood cells.
Reduced white blood cell counts may increase the risk of infection, low platelet counts may increase bleeding, and low red blood cell counts may cause anemia and fatigue.
Lanvis can also cause serious liver complications, particularly when used continuously for extended periods.
These complications may include liver injury involving small blood vessels, sometimes leading to portal hypertension or sinusoidal obstruction syndrome.
For this reason, long-term continuous maintenance therapy is generally not recommended.
Some people have genetic variations affecting enzymes called TPMT and NUDT15. These variations may increase sensitivity to thioguanine and the risk of severe bone marrow suppression.
Your healthcare provider may consider genetic testing, blood cell counts, and liver function monitoring when planning treatment.
Lanvis is used to treat certain acute leukemias by interfering with DNA and RNA production in cancer cells. Its treatment benefits must be balanced against important risks, including bone marrow suppression and liver toxicity.
Lanvis is a prescription chemotherapy medication used to treat certain types of acute leukemia, including acute myeloid leukemia (AML). It belongs to a class of medications called antimetabolites, which interfere with the growth and multiplication of cancer cells.
Lanvis is available as an oral tablet and is usually taken once daily or according to a specific chemotherapy schedule prescribed by your healthcare provider.
The appropriate dosage and duration of treatment depend on the type of leukemia, your response to treatment, your blood cell counts, and whether you are receiving other chemotherapy medications.
Your healthcare provider will determine how much Lanvis you should take and how long your treatment should continue. The medication may be used alongside other chemotherapy drugs as part of a carefully planned treatment regimen.
Take Lanvis at approximately the same time on each scheduled treatment day to help maintain a consistent routine.
Follow the instructions on your prescription label carefully. If you do not understand your dosage or treatment schedule, ask your healthcare provider or pharmacist for clarification.
Lanvis should be taken exactly as prescribed by your cancer treatment team.
Because thioguanine is a cytotoxic chemotherapy medication, taking too much or using it incorrectly can cause serious complications, including bone marrow suppression and liver toxicity.
Follow these steps when taking Lanvis:
Do not crush or split Lanvis tablets unless your healthcare provider or pharmacist gives specific instructions for safe handling.
If a tablet needs to be manipulated because you have difficulty swallowing, ask your cancer treatment team about an appropriate method. Chemotherapy medications require special handling to reduce unnecessary exposure.
Lanvis works by interfering with the production and function of DNA and RNA inside rapidly dividing cells.
Leukemia cells multiply abnormally, and thioguanine helps prevent them from growing and reproducing.
When Lanvis is prescribed as part of a chemotherapy regimen, following the treatment schedule helps ensure the medication is administered as intended.
However, unlike medications used continuously for chronic conditions, Lanvis may be prescribed in treatment cycles with planned breaks.
These breaks allow your healthcare team to evaluate your response and monitor for side effects.
Do not continue taking Lanvis beyond your prescribed treatment period.
Your healthcare provider may adjust or temporarily interrupt treatment based on your blood cell counts, liver function, or other clinical findings.
Lanvis may cause nausea, vomiting, or loss of appetite during treatment. These side effects can occur because chemotherapy medications affect rapidly dividing cells, including healthy cells lining the digestive tract.
If you experience mild nausea, tell your healthcare provider. Your cancer treatment team may recommend medication to prevent or relieve nausea and vomiting.
You should continue following your prescribed treatment schedule unless your healthcare provider instructs you to change it. However, do not ignore severe or persistent vomiting, particularly if you cannot keep fluids or medication down.
If you vomit shortly after taking Lanvis, contact your healthcare provider or cancer treatment team for instructions.
Do not automatically take another tablet to replace the dose you may have vomited. Some medication may already have been absorbed, and taking an additional dose could increase the risk of serious side effects.
Your healthcare provider will determine whether you should repeat the dose or wait until your next scheduled treatment.
If you forget to take a dose of Lanvis, take it as soon as you remember unless it is almost time for your next scheduled dose.
If your next dose is approaching, skip the missed dose and return to your regular treatment schedule.
Never take two doses together to make up for a missed dose.
Taking extra Lanvis may increase the risk of serious side effects, including reduced blood cell production and liver toxicity.
If you miss two doses, contact your healthcare provider for further instructions, as recommended in the Canadian Lanvis product monograph.
If your cancer treatment team has provided different missed-dose instructions for your specific chemotherapy regimen, follow those instructions instead.
Do not independently extend your treatment schedule or add extra doses to replace missed tablets.
Do not stop taking Lanvis without consulting your healthcare provider.
Even if your symptoms improve, leukemia cells may still be present in your blood or bone marrow.
Your healthcare team uses blood tests, bone marrow examinations, and other clinical findings to assess how well treatment is working.
Feeling better does not necessarily mean that your leukemia has entered remission.
However, Lanvis may need to be temporarily interrupted, reduced, or discontinued if serious side effects develop.
For example, your healthcare provider may adjust treatment if your blood cell counts become dangerously low or liver function tests show concerning changes.
Lanvis is generally prescribed as part of a carefully planned chemotherapy regimen rather than continued indefinitely.
Your healthcare provider will determine when treatment should be completed or changed.
Regular blood tests are essential because Lanvis can affect the bone marrow and liver.
One of its most important side effects is myelosuppression, which means the bone marrow produces fewer healthy blood cells.
This may reduce the number of red blood cells, white blood cells, and platelets in your bloodstream.
Low red blood cell counts can cause anemia and fatigue, while low white blood cell counts increase the risk of infection. Low platelet counts can cause unusual bruising or bleeding.
Your healthcare provider will monitor your complete blood count (CBC) to identify these changes.
Lanvis can also cause liver toxicity, so liver function tests may be recommended throughout treatment.
These tests help your healthcare provider determine whether your medication dosage remains appropriate.
Contact your cancer treatment team immediately if you develop a fever, unusual bruising, persistent bleeding, yellowing of the skin or eyes, or severe weakness.
Lanvis is a cytotoxic chemotherapy medication that requires careful medical supervision.
Tell your healthcare provider about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you take.
Your healthcare provider should also know if you have liver disease, kidney problems, a history of serious infections, or previous treatment with other chemotherapy medications.
Some individuals have inherited differences in enzymes called TPMT and NUDT15 that affect how thioguanine is processed. These variations may increase the risk of severe bone marrow suppression.
Your healthcare team may recommend appropriate testing and closer monitoring when necessary.
Lanvis may also harm an unborn baby. Tell your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.
Do not receive vaccinations during treatment without discussing them with your cancer treatment team.
Lanvis should be taken exactly according to your prescribed chemotherapy schedule. Taking the correct dose, reporting vomiting or missed doses, and attending regular blood tests are important for maintaining treatment safety.
Lanvis (thioguanine) is available in the following forms and strength:
Lanvis is a prescription chemotherapy medication used to treat certain types of acute leukemia, including acute myeloid leukemia (AML).
It belongs to a class of medications called antimetabolites, specifically purine analogues. These medications interfere with DNA and RNA production, making it more difficult for rapidly dividing cancer cells to grow and multiply.
Although Lanvis can help treat leukemia, it may also affect healthy cells, particularly those in the bone marrow, digestive system, and liver.
Some side effects can be serious or life-threatening. For this reason, Lanvis should only be prescribed and monitored by healthcare providers experienced in cancer chemotherapy.
Before starting treatment, tell your healthcare provider about any medical conditions, allergies, infections, or medications you are taking.
One of the most important risks associated with Lanvis is bone marrow suppression, also called myelosuppression.
Bone marrow is the soft tissue inside your bones that produces red blood cells, white blood cells, and platelets.
Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets help control bleeding.
Lanvis works by interfering with DNA production in rapidly dividing cells. Although this helps destroy leukemia cells, it can also affect healthy blood-forming cells.
As a result, the bone marrow may produce fewer normal blood cells.
This can lead to several complications:
Because myelosuppression can develop during treatment, regular blood tests are necessary.
Your healthcare provider will monitor your complete blood count (CBC) to determine whether your blood cell levels remain within an acceptable range.
Your chemotherapy dose may need to be reduced, delayed, or temporarily stopped if your blood cell counts become too low.
Contact your cancer treatment team immediately if you develop a fever, unusual bleeding, unexplained bruising, or severe weakness.
These symptoms may indicate complications related to reduced blood cell production.
Lanvis can weaken the immune system by reducing the number of healthy white blood cells.
White blood cells normally help protect your body against bacteria, viruses, fungi, and other microorganisms.
When white blood cell counts become low, your body may have difficulty fighting infections.
This condition is especially concerning when the number of neutrophils, a type of white blood cell, becomes very low.
Neutrophils are important for defending the body against bacterial and fungal infections.
Possible signs of infection include fever, chills, sore throat, persistent coughing, mouth sores, painful urination, and unusual tiredness.
Some people with severe neutropenia may develop serious infections without the usual signs of inflammation.
Because infections can progress rapidly during chemotherapy, even a mild fever may require urgent evaluation.
If your temperature reaches 38°C (100.4°F) or higher, contact your cancer treatment team immediately or follow its emergency fever instructions.
Tell your healthcare provider if you have an active infection before starting Lanvis.
You should also discuss vaccinations before treatment. Live vaccines are generally avoided during significant chemotherapy-related immunosuppression because they may cause infection in people with weakened immune systems.
Your healthcare provider can advise when vaccinations are appropriate.
Lanvis may cause serious liver complications, particularly when used continuously for extended periods.
The liver helps process medications, remove waste products, and regulate important metabolic functions.
Thioguanine can damage small blood vessels within the liver, interfering with normal blood flow.
This may cause a condition called hepatic sinusoidal obstruction syndrome, also known as hepatic veno-occlusive disease.
In this condition, damage to the small blood vessels of the liver restricts blood flow and may cause fluid accumulation.
Lanvis may also contribute to portal hypertension, which occurs when blood pressure increases in the blood vessels supplying the liver.
Possible symptoms include:
Liver complications may also cause abnormal liver function test results.
However, some forms of thioguanine-related liver injury can develop without substantial increases in liver enzymes.
Your healthcare provider will monitor your liver function and other signs of liver injury during treatment.
Lanvis is generally not recommended for long-term continuous maintenance therapy because this substantially increases the risk of serious liver toxicity.
Contact your cancer treatment team promptly if you develop jaundice, abdominal swelling, rapid weight gain, or persistent upper abdominal pain.
Lanvis may cause digestive side effects because chemotherapy can affect rapidly dividing cells lining the stomach and intestines.
The digestive tract contains cells that naturally replace themselves frequently.
Thioguanine may interfere with this normal renewal process, leading to irritation and inflammation.
Common digestive symptoms may include nausea, vomiting, diarrhea, reduced appetite, and mouth sores.
Some people experience mild discomfort, while others develop symptoms that interfere with eating or drinking.
Persistent vomiting and diarrhea may cause dehydration and electrolyte imbalances.
Your healthcare provider may recommend medications to manage nausea or other digestive symptoms.
Do not take additional Lanvis tablets if you vomit shortly after a dose unless your cancer treatment team specifically instructs you to do so.
Rarely, serious intestinal complications, including severe inflammation of the colon and bowel perforation, have been reported during thioguanine treatment.
A bowel perforation occurs when a hole develops through the wall of the intestine.
Seek urgent medical attention if you experience severe abdominal pain, persistent vomiting, bloody stools, or a swollen abdomen accompanied by significant discomfort.
Your healthcare provider may need to evaluate whether the symptoms are related to Lanvis, another chemotherapy medication, or the underlying illness.
Do not take Lanvis if you have a known allergy to thioguanine or another ingredient in the medication.
An allergic reaction occurs when the immune system responds abnormally to a substance.
Possible symptoms include a new skin rash, itching, hives, facial swelling, or difficulty breathing.
Although severe allergic reactions are uncommon, they can require emergency treatment.
A potentially life-threatening allergic reaction called anaphylaxis can cause swelling of the throat, breathing difficulties, and a sudden drop in blood pressure.
Severe blistering skin reactions, including Stevens-Johnson syndrome (SJS), are sometimes mentioned in broader chemotherapy safety discussions. However, SJS is not established as a characteristic adverse reaction of Lanvis in the Canadian product monograph.
This distinction is important because not every serious reaction associated with chemotherapy in general is a confirmed risk of thioguanine specifically.
Nevertheless, a widespread painful rash, blistering, or peeling skin requires urgent medical assessment regardless of its cause.
Seek emergency medical attention if you develop difficulty breathing, swelling of the tongue or throat, or a severe blistering skin reaction.
Tell your healthcare provider about any previous allergic reactions to cancer medications before starting treatment.
Lanvis can harm a developing baby because it interferes with DNA production and cell division.
These processes are particularly important during pregnancy, when fetal cells are growing and developing rapidly.
Exposure to cytotoxic chemotherapy during pregnancy may increase the risk of pregnancy loss, birth defects, or other complications, depending on the medication and timing of exposure.
Thioguanine should generally be avoided during pregnancy unless a specialist determines that treatment is essential for a serious medical condition.
Because acute leukemia may require urgent treatment, decisions about chemotherapy during pregnancy must be made individually by the cancer treatment team and appropriate pregnancy specialists.
Tell your healthcare provider if you are pregnant, think you may be pregnant, or are planning to become pregnant.
Effective contraception is important during treatment. Your healthcare provider will explain which contraceptive methods to use and how long contraception should continue after treatment.
Do not stop or delay prescribed leukemia treatment without speaking with your cancer treatment team.
Breastfeeding is not recommended while taking Lanvis because thioguanine is a cytotoxic chemotherapy medication.
It is not known whether significant amounts of thioguanine enter human breast milk.
However, because the medication can interfere with cell division and cause serious adverse effects, exposure to a nursing infant should be avoided.
A baby’s developing organs and tissues may be particularly vulnerable to medications that affect DNA production.
If you are breastfeeding or planning to breastfeed, tell your healthcare provider before starting Lanvis.
Your healthcare provider can explain when breastfeeding should be stopped and whether it may be resumed after treatment.
The appropriate waiting period depends on the treatment regimen and specialist guidance.
Do not breastfeed during Lanvis treatment unless your specialist has explicitly confirmed that it is safe.
Lanvis may interact with medications that affect bone marrow function, immune activity, or thioguanine metabolism.
Certain combinations can increase the risk of serious side effects.
For example, other chemotherapy medications may also suppress bone marrow activity.
When Lanvis is combined with these treatments, the reduction in blood cell counts may become more severe.
Some medications used to treat inflammatory bowel disease, including mesalamine, sulfasalazine, and olsalazine, may interfere with enzymes involved in thiopurine metabolism and increase the risk of bone marrow toxicity.
An important distinction is that thioguanine does not have the same interaction with allopurinol as mercaptopurine and azathioprine. Do not automatically apply interaction warnings from those medications to Lanvis.
Your healthcare provider will review your complete medication list and treatment regimen to identify clinically important interactions.
Tell your cancer treatment team about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you take.
Do not start a new medication or supplement without checking with your healthcare provider or oncology pharmacist.
Lanvis may cause anemia and bleeding problems because it suppresses normal blood cell production in the bone marrow.
Anemia develops when there are not enough healthy red blood cells to carry oxygen throughout the body.
This may cause persistent fatigue, weakness, pale skin, dizziness, or shortness of breath.
Lanvis may also reduce platelet counts, causing a condition called thrombocytopenia.
Platelets help blood form clots and stop bleeding after an injury.
When platelet counts become too low, you may bruise more easily or experience bleeding that takes longer than usual to stop.
Possible warning signs include frequent nosebleeds, bleeding gums, unexplained bruises, tiny red or purple spots on the skin, and blood in the urine or stool.
Your healthcare provider will monitor your blood cell counts throughout treatment.
Contact your cancer treatment team immediately if you experience unusual bleeding, unexplained bruising, or increasing weakness.
Seek emergency medical attention for bleeding that will not stop, vomiting blood, or black, tarry stools.
Thioguanine interferes with DNA production in rapidly dividing cells.
Although this action helps treat leukemia, it can also affect the genetic material of healthy cells.
Because of its effects on DNA, thioguanine is considered potentially mutagenic and carcinogenic.
A mutagenic substance can cause changes in genetic material, while a carcinogenic substance may increase the risk of cancer.
However, the exact risk of developing secondary cancers from Lanvis alone is not well established.
People receiving chemotherapy may also be exposed to several other cancer treatments, making it difficult to determine which medication contributes to long-term complications.
Although secondary leukemia and lymphoma are sometimes discussed as possible complications of cancer treatment, they should not be presented as established, specific side effects of Lanvis without supporting evidence.
Your healthcare provider will consider the potential long-term risks alongside the benefits of treating leukemia.
Regular follow-up appointments remain important during and after cancer treatment.
Lanvis may occasionally cause skin-related side effects, including rashes and increased sensitivity to sunlight.
Photosensitivity occurs when the skin reacts more strongly than usual to ultraviolet radiation.
Some people may experience redness, itching, or sunburn-like reactions after spending time outdoors.
Photosensitivity and skin rash have been reported with thioguanine, although they are considered uncommon.
To protect your skin, use a broad-spectrum sunscreen with an SPF of at least 30, wear protective clothing, and avoid prolonged exposure to intense sunlight.
Tell your healthcare provider if you develop a new rash, persistent itching, unusual redness, or other unexpected skin changes.
Because chemotherapy medications may also cause serious reactions, do not assume that every rash is harmless.
Seek urgent medical attention if a rash is accompanied by fever, blistering, peeling skin, or swelling of the face or throat.
Some people receiving chemotherapy may experience neurological symptoms, including weakness, confusion, dizziness, or coordination difficulties.
Neurological symptoms can affect the brain, nerves, or muscles.
However, peripheral neuropathy and disorientation are not established as common or characteristic side effects of Lanvis.
Peripheral neuropathy refers to damage affecting nerves outside the brain and spinal cord. It may cause numbness, tingling, burning sensations, or weakness, particularly in the hands and feet.
These symptoms may develop for several reasons during leukemia treatment, including other chemotherapy medications, infections, metabolic abnormalities, or the underlying disease.
Tell your healthcare provider if you develop persistent tingling, numbness, dizziness, or difficulty walking.
Seek emergency medical attention if you experience sudden confusion, seizures, loss of consciousness, or new weakness affecting one side of the body.
Your healthcare team will determine whether these symptoms are related to Lanvis, another treatment, or a separate medical condition.
Breathing problems during leukemia treatment require careful medical evaluation.
People receiving chemotherapy may develop respiratory symptoms because of infections, anemia, fluid accumulation, or other treatment-related complications.
Pneumonitis is inflammation of lung tissue, while pulmonary fibrosis refers to scarring that can make breathing more difficult.
Although these conditions can occur with certain cancer treatments, pneumonitis and pulmonary fibrosis are not well-established direct adverse effects of Lanvis in its standard prescribing information.
Therefore, they should not automatically be attributed to thioguanine.
Nevertheless, new respiratory symptoms may indicate a serious medical problem, particularly in someone with chemotherapy-related immunosuppression.
Contact your cancer treatment team promptly if you develop persistent coughing, fever, worsening breathlessness, or chest discomfort.
Seek emergency medical attention if you experience severe difficulty breathing, chest pain, or sudden respiratory distress.
Vision changes may occur during cancer treatment for several reasons, including infections, bleeding, other medications, or underlying medical conditions.
Cataracts cause clouding of the eye’s natural lens, while retinal damage affects the light-sensitive tissue at the back of the eye.
However, cataracts and retinal damage are not recognized as characteristic toxic effects of thioguanine in major Lanvis product references.
These complications should not be described as confirmed Lanvis side effects without appropriate clinical evidence.
If you experience blurred vision, double vision, eye pain, or other changes in eyesight during treatment, inform your healthcare provider.
Your healthcare team may recommend an eye examination to identify the cause.
Seek emergency medical attention if you experience sudden vision loss, severe eye pain, or vision changes accompanied by neurological symptoms.
Some people have inherited genetic variations that affect how their bodies process thioguanine.
Two important genes are TPMT and NUDT15.
These genes influence the activity of proteins involved in processing thiopurine medications.
People with reduced TPMT or NUDT15 activity may accumulate higher amounts of active thioguanine metabolites.
This can substantially increase the risk of severe bone marrow suppression, including dangerously low white blood cell and platelet counts.
Your healthcare provider may recommend genetic testing before treatment or if you develop unusually severe blood cell abnormalities.
Depending on the results, your healthcare provider may adjust your chemotherapy dosage or recommend a different treatment.
Genetic testing does not replace regular blood tests. Even patients without these genetic variations can develop serious bone marrow suppression.
Lanvis may contribute to rapid destruction of leukemia cells during effective chemotherapy treatment.
When large numbers of cancer cells break down quickly, they release substances into the bloodstream.
This can cause significant changes in potassium, phosphate, calcium, and uric acid levels.
The resulting condition is called tumor lysis syndrome.
Tumor lysis syndrome can affect the kidneys, muscles, nerves, and heart.
Thioguanine treatment may also cause elevated uric acid levels, known as hyperuricemia, particularly during periods when leukemia cells are being destroyed rapidly.
Excess uric acid can contribute to kidney injury.
Your healthcare team may monitor your kidney function and electrolyte levels during treatment.
Preventive measures may include appropriate hydration and medications that help control uric acid levels.
Tell your healthcare provider if you develop reduced urination, persistent nausea, muscle cramps, or unusual weakness.
Seek emergency medical attention for seizures, fainting, or symptoms of a serious heart rhythm disturbance.
Contact your cancer treatment team promptly if you experience persistent nausea, vomiting, diarrhea, unusual fatigue, worsening weakness, skin irritation, or new neurological symptoms.
Some symptoms require urgent attention because Lanvis can suppress blood cell production and affect liver function.
Seek immediate medical advice if you develop a fever of 38°C (100.4°F) or higher, unusual bruising, bleeding, jaundice, abdominal swelling, or severe abdominal pain.
Seek emergency medical attention if you experience severe difficulty breathing, uncontrolled bleeding, seizures, sudden confusion, or symptoms of a serious allergic reaction.
Never stop, restart, or adjust your chemotherapy dosage without instructions from your cancer treatment team, except when emergency medical guidance requires treatment to be withheld.
The length of treatment with Lanvis varies depending on the type of leukemia being treated, the chemotherapy regimen prescribed, and how your body responds to treatment. Lanvis is a prescription chemotherapy medication used to treat certain types of acute leukemia, including acute myeloid leukemia (AML). It works by interfering with DNA and RNA production, helping prevent cancer cells from growing and multiplying. Lanvis is often used alongside other chemotherapy medications as part of a planned treatment regimen. Some people may take Lanvis for several days or weeks during a specific chemotherapy cycle, while others may receive additional treatment cycles over several months. However, Lanvis is generally not recommended for long-term continuous maintenance treatment because prolonged use can increase the risk of serious liver complications. Your healthcare provider will determine the appropriate treatment duration based on your leukemia type, blood cell counts, liver function, and response to chemotherapy. Regular blood tests and, when necessary, bone marrow examinations help your healthcare team evaluate whether treatment is working. Do not continue taking Lanvis beyond your prescribed treatment schedule or stop taking it without consulting your healthcare provider.
Lanvis tablets can generally be taken with or without food, depending on your healthcare provider’s instructions. Some people prefer taking the medication with food to help reduce stomach discomfort, particularly if they experience nausea during chemotherapy. However, food may affect how certain medications are absorbed, so following a consistent routine is important. If your healthcare provider has instructed you to take Lanvis with food, continue following that recommendation throughout treatment. If you have been advised to take the medication on an empty stomach, follow those instructions instead. Swallow the tablet with water, and take it at approximately the same time on each scheduled treatment day. Do not crush, chew, or split Lanvis tablets unless your healthcare provider or oncology pharmacist specifically instructs you to do so. Thioguanine is a cytotoxic medication that requires careful handling. If you experience nausea or vomiting after taking Lanvis, tell your healthcare provider. Do not automatically repeat a dose if you vomit shortly after taking it, because some medication may already have been absorbed. Your cancer treatment team can advise whether any changes to your medication schedule are necessary.
Yes. You may need to avoid certain activities while taking Lanvis because chemotherapy can reduce healthy blood cell counts and weaken your body’s ability to fight infections. Lanvis can cause bone marrow suppression, also called myelosuppression. This occurs when the bone marrow produces fewer red blood cells, white blood cells, and platelets. Low white blood cell counts can increase your risk of developing infections, while low platelet counts can make you more likely to bruise or bleed. For this reason, you should take additional precautions during treatment. Avoid close contact with people who have contagious illnesses, including colds, influenza, or other respiratory infections. Wash your hands regularly and follow any infection-prevention instructions provided by your cancer treatment team. If your platelet count is low, avoid contact sports, high-impact exercise, or activities that could cause falls, cuts, or injuries. You may also need to use extra caution when shaving, brushing your teeth, or handling sharp objects. However, you do not necessarily need to avoid all physical activity during chemotherapy. Gentle walking and other low-impact activities may be appropriate when your healthcare provider considers them safe. The activities you can perform will depend on your blood cell counts, energy levels, symptoms, and overall health. If you develop a fever of 38°C (100.4°F) or higher, contact your cancer treatment team immediately or follow its emergency fever instructions. Your healthcare provider can recommend appropriate activity restrictions based on your condition.
It is generally best to avoid alcohol while taking Lanvis, particularly because the medication can cause serious liver complications. The liver plays an important role in processing medications, removing harmful substances, and maintaining normal body functions. Lanvis may cause liver toxicity, especially when used continuously for extended periods. Alcohol is also processed by the liver. Drinking alcohol during chemotherapy may place additional strain on the liver and make certain treatment-related side effects more difficult to manage. Alcohol may also worsen nausea, vomiting, diarrhea, dehydration, and fatigue. According to Cancer Care Ontario, drinking alcohol during thioguanine treatment may increase certain side effects and interfere with treatment. However, there is no established amount of alcohol that is considered safe for everyone receiving Lanvis. Your individual risk depends on your liver function, prescribed chemotherapy regimen, other medications, and overall health. Avoid alcohol unless your cancer treatment team confirms that drinking is appropriate for you. If you have existing liver disease or abnormal liver function tests, your healthcare provider may strongly recommend avoiding alcohol completely.
You will need regular follow-up appointments and blood tests while taking Lanvis because the medication can affect your bone marrow, liver, and other body functions. The frequency of these appointments depends on your type of leukemia, chemotherapy schedule, response to treatment, and risk of side effects. During active treatment, your healthcare provider may recommend frequent blood tests to monitor your complete blood count (CBC). These tests measure red blood cells, white blood cells, and platelets. Lanvis can reduce the production of healthy blood cells, increasing the risk of anemia, infections, and bleeding. Monitoring helps your healthcare team identify these complications before they become severe. Your healthcare provider will also monitor your liver function because thioguanine may cause liver damage, particularly with prolonged treatment. Cancer Care Ontario recommends checking complete blood counts at baseline and at least weekly during treatment. Liver and kidney function are also assessed at baseline and during follow-up visits. Your treating specialist may recommend more frequent testing depending on your condition. Your healthcare provider may also arrange bone marrow examinations to determine how well your leukemia is responding to chemotherapy. These examinations help assess whether the number of leukemia cells has decreased and whether normal blood cell production is recovering. During your appointments, your healthcare team may ask about nausea, vomiting, unusual bruising, bleeding, fever, fatigue, abdominal discomfort, or other symptoms. If your blood cell counts become dangerously low or your liver function changes significantly, your healthcare provider may reduce your dosage, delay treatment, or recommend another medication. Attend all scheduled appointments and blood tests, even if you feel well. Some serious complications of Lanvis treatment may develop before noticeable symptoms appear. Contact your cancer treatment team immediately if you develop a fever, unexplained bleeding, yellowing of the skin or eyes, severe abdominal pain, or unusual weakness. Regular monitoring helps your healthcare provider evaluate treatment effectiveness, recognize complications early, and make appropriate adjustments to your chemotherapy plan.
| Generic name: | Thioguanine |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 40mg |
| Quantities Available: | 25, 100 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Lanvis (thioguanine) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Lanvis is commonly prescribed in dosages of 40 mg, taken once daily. For a 90-day supply, this means you would order 90 tablets (90 days x 1 tablet per day of 20 mg).
No, we do not sell thioguanine directly on our website. However, you can still enjoy low prices on Lanvis, which contains thioguanine as an active ingredient. To purchase Lanvis, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Lanvis (thioguanine) to both the United States and Puerto Rico.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Lanvis (Thioguanine). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Lanvis (Thioguanine).
REVIEWS